2018 related articles for article (PubMed ID: 28875844)
1. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.
Palazzolo S; Bayda S; Hadla M; Caligiuri I; Corona G; Toffoli G; Rizzolio F
Curr Med Chem; 2018; 25(34):4224-4268. PubMed ID: 28875844
[TBL] [Abstract][Full Text] [Related]
2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
3. Inorganic Nanoparticles for Cancer Therapy: A Transition from Lab to Clinic.
Bayda S; Hadla M; Palazzolo S; Riello P; Corona G; Toffoli G; Rizzolio F
Curr Med Chem; 2018; 25(34):4269-4303. PubMed ID: 29284391
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel-loaded micelles enhance transvascular permeability and retention of nanomedicines in tumors.
Danhier F; Danhier P; De Saedeleer CJ; Fruytier AC; Schleich N; des Rieux A; Sonveaux P; Gallez B; Préat V
Int J Pharm; 2015 Feb; 479(2):399-407. PubMed ID: 25578367
[TBL] [Abstract][Full Text] [Related]
5. Soft matter assemblies as nanomedicine platforms for cancer chemotherapy: a journey from market products towards novel approaches.
Jäger E; Giacomelli FC
Curr Top Med Chem; 2015; 15(4):328-44. PubMed ID: 25633209
[TBL] [Abstract][Full Text] [Related]
6. Nanodrugs used in cancer therapy.
Kopeckova K; Eckschlager T; Sirc J; Hobzova R; Plch J; Hrabeta J; Michalek J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2019 Jun; 163(2):122-131. PubMed ID: 30967685
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicine for cancer diagnosis and therapy: advancement, success and structure-activity relationship.
Bhise K; Sau S; Alsaab H; Kashaw SK; Tekade RK; Iyer AK
Ther Deliv; 2017 Nov; 8(11):1003-1018. PubMed ID: 29061101
[TBL] [Abstract][Full Text] [Related]
8. Tumor-targeted nanomedicines for cancer theranostics.
Arranja AG; Pathak V; Lammers T; Shi Y
Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
[TBL] [Abstract][Full Text] [Related]
9. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
[TBL] [Abstract][Full Text] [Related]
10. Microfluidic and lab-on-a-chip preparation routes for organic nanoparticles and vesicular systems for nanomedicine applications.
Capretto L; Carugo D; Mazzitelli S; Nastruzzi C; Zhang X
Adv Drug Deliv Rev; 2013 Nov; 65(11-12):1496-532. PubMed ID: 23933616
[TBL] [Abstract][Full Text] [Related]
11. Nanomedicines for the treatment of hematological malignancies.
Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer.
Gurunathan S; Kang MH; Qasim M; Kim JH
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347840
[TBL] [Abstract][Full Text] [Related]
13. Nano-Medicine as a Newly Emerging Approach to Combat Human Immunodeficiency Virus (HIV).
Saravanan M; Asmalash T; Gebrekidan A; Gebreegziabiher D; Araya T; Hilekiros H; Barabadi H; Ramanathan K
Pharm Nanotechnol; 2018; 6(1):17-27. PubMed ID: 29424324
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicines based drug delivery systems for anti-cancer targeting and treatment.
Jain V; Jain S; Mahajan SC
Curr Drug Deliv; 2015; 12(2):177-91. PubMed ID: 25146439
[TBL] [Abstract][Full Text] [Related]
15. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
16. Drug Delivery Systems Based on Polymeric Micelles and Ultrasound: A Review.
Tanbour R; Martins AM; Pitt WG; Husseini GA
Curr Pharm Des; 2016; 22(19):2796-807. PubMed ID: 26898742
[TBL] [Abstract][Full Text] [Related]
17. Advances in nanomedicine towards clinical application in oncology and immunology.
Herreros E; Morales S; Cortés C; Cabaña M; Peñaloza JP; Jara L; Geraldo D; Otero C; Fernández-Ramires R
Curr Pharm Biotechnol; 2014; 15(9):864-79. PubMed ID: 25213311
[TBL] [Abstract][Full Text] [Related]
18. Applications of nanosystems to anticancer drug therapy (Part II. Dendrimers, micelles, lipid-based nanosystems).
Ruiz ME; Gantner ME; Talevi A
Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):99-128. PubMed ID: 23578193
[TBL] [Abstract][Full Text] [Related]
19. Organic nanocarriers for cancer drug delivery.
López-Dávila V; Seifalian AM; Loizidou M
Curr Opin Pharmacol; 2012 Aug; 12(4):414-9. PubMed ID: 22465543
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic behaviors of soft nanoparticulate formulations of chemotherapeutics.
Sarkar M; Wang Y; Ekpenyong O; Liang D; Xie H
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023 Mar; 15(2):e1846. PubMed ID: 35979879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
